Search

everythinglearnresearchcommunity

for

Search:↓

RU58841 is discussed as a potential hair loss treatment, with comparisons to finasteride. There is interest in leaked trial data, but no official clinical validation or approval for RU58841.

Pyrilutamide Phase 3 approved, starting early 2022 with 416 subjects for 24 weeks. Drug potentially better than RU and Breezula, with some users reporting no side effects.

The conversation discusses concerns about Scube3's effectiveness and potential cancer link. It questions whether Scube3 can regrow hair and how well it works according to researchers.

RU58841, a potential hair loss treatment, was not commercialized due to marketability issues and lack of long-term safety data. Concerns about its formulation and delivery methods further complicate its use.

SCUBE3 is a potential hair loss treatment that people are hopeful about. It may provide a solution without the side effects of finasteride.

A 25-year-old male experiencing diffuse thinning is advised to address high TSH levels and low iron, and consider treatments like finasteride. Weight loss and improved diet are also suggested to potentially help with hair health.

A 31-year-old male shared his 3-year progress using finasteride 1 mg daily, with additional treatments including nutrafol, multivitamins, vitamin D, marine collagen, PRP scalp injections, micro-needling, and Nizoral. He experienced temporary libido issues but currently has no side effects.

The individual is experiencing hair loss and has a vitamin D deficiency, with levels at 7.49ng/ml or 26nmol/l. They are unsure if the deficiency is causing the hair loss and are seeking advice on vitamin D supplementation.

The post discusses the use of El-Cranell, which contains Alfatradiol, and Quercetin as a treatment for hair loss. The user is seeking recommendations on the amount of Quercetin to add to the solution. The conclusion of the document is that Quercetin has been shown to stimulate hair growth and inhibit DHT, and combining it with zinc/copper may have a synergistic effect.

A study that outlines the full model for androgenic alopecia (AGA) which links DHT to cellular senescence in dermal papilla cells, and suggests black chokeberry as a source of cyanidin 3-O-arabinoside polyphenol with potential anti-oxidant properties that could reverse this process. The post encourages reaching out to experts in anti-aging and longevity to research treatments involving the polyphenol.

A user's experience with aggressive hair loss from age 18-22, and possible treatments to combat this such as Dut, oral minoxidil, and finasteride.

Results for Amplifica's AMP-303 hair loss treatment study are expected late summer 2024. The study, fully enrolled in Q1 2024, focuses on safety and tolerability.

A 17-year-old is experiencing diffuse thinning, dandruff, body hair shedding, and other symptoms, possibly linked to seborrheic dermatitis or telogen effluvium. They are using ketoconazole shampoo and considering blood tests to check for thyroid issues or deficiencies.

A user improved their hair loss from NW3+ to NW1.5 over three years using a regimen of dutasteride, finasteride, Nizoral, biotin, and collagen. They experienced some side effects and adjusted dosages over time, and noted additional benefits like better skin and muscle gain.

The post discusses the potential of upregulating aromatase to treat hair loss, suggesting that increasing CCL2 levels through Vitamin D or microneedling might help. The user questions why microneedling doesn't work for everyone, especially those with advanced hair loss.

Pyrilutamide is a selective AR antagonist with a high binding affinity, making it effective in competing with DHT for androgen receptors. The 1% concentration is more effective than the 0.5%, but the latter may suffice for mild hair loss; the drug is considered a good option for those avoiding 5AR blockers due to side effects.

A 21-year-old shared their one-year hair loss treatment journey, using finasteride, a multivitamin, cold water hair washes, peppermint and jojoba oil, zinc, iron, L-arginine, vitamin D, and ashwagandha. They advise seeing a doctor for finasteride, considering lifestyle changes before minoxidil, getting blood work, talking about the issue with friends, and sticking to a treatment plan for at least six months.

The user experienced significant hair regrowth using oral finasteride 1.25mg daily and a Capillus RX laser cap, with no side effects. Improvement was noticed after 9 months, and shedding stopped after the initial 4-5 months.

RU58841 can be ordered as a powder and compounded at home, but it should be stored at room temperature to avoid crystallization. Pyraulatmide may follow a similar principle.

A 21-year-old from Germany is experiencing a receding hairline and is considering treatments like Finasteride and Minoxidil. They are unsure whether to consult a general practitioner or dermatologist and are concerned about being taken seriously due to their age.

KX-826/pyrilutamide is undergoing an additional one-year safety and efficacy trial in China after a six-month study. Some participants speculate on the reasons for the extended trial and discuss the potential of other treatments.

GT20029 is a new hair loss treatment in Phase 3 trials in China, using PROTAC technology to target androgen receptors, potentially with fewer side effects than finasteride and minoxidil. VDPHL01, a second-generation minoxidil, is also mentioned as potentially more effective.

RU58841, an anti-androgenic compound, showed early promise for treating alopecia but faced challenges after its patent in 1997. Despite advancing to Phase II trials, safety concerns and financial struggles led Aventis to abandon its development. Proskelia, which later merged into ProStrakan, couldn't prioritize the drug, leading to its eventual stagnation and failure to reach the market.

A 19-year-old female is experiencing significant hair loss, with symptoms including alternating hair colors and thinning body hair. She seeks advice on coping and potential treatments, with suggestions to consult a dermatologist and check thyroid and hormone levels.

A 21 year old male who has been using finasteride and minoxidil for 3 months to treat hair loss, and others sharing their experiences with the same treatments.

A male in his early 20s with CCCA (scarring alopecia) started treatment with Finasteride, Fluocinolone, and Doxycycline. Steroid injections were suggested but not yet done.

Chime Biologics and Hope Medicine are speeding up the launch of a first-in-class antibody drug, HMI-115, for endometriosis and androgenic alopecia. The treatment involves a series of subcutaneous injections, has shown promising results in phase 1, and continues to promote hair regrowth even after the treatment is stopped.

CB-03-01 is considered a failed treatment for hair loss, with future hopes pinned on PP-405 and GT-20029, expected by 2030. Alternatives like hair transplants and SMP are discussed, while some users express frustration over the slow progress of treatments like Breezula.

The conversation is about the release of Phase 3 trial results for pyrilutamide in China for treating hair loss. The user is inquiring if the actual results have been posted, noting that a recent release did not contain them.

A 21-year-old experiencing aggressive hair shedding is considering treatments like Propecia (finasteride) and Rogaine (minoxidil) to slow or stop hair loss. Recommendations include using these treatments along with Nizoral Shampoo, hair vitamins, and a derma roller to maintain and potentially regrow hair.